149 related articles for article (PubMed ID: 24155758)
1. Silencing of fanconi anemia complementation group f exhibits potent chemosensitization of mitomycin C activity in breast cancer cells.
Yu J; Zhao L; Li Y; Li N; He M; Bai X; Yu Z; Zheng Z; Mi X; Wang E; Wei M
J Breast Cancer; 2013 Sep; 16(3):291-9. PubMed ID: 24155758
[TBL] [Abstract][Full Text] [Related]
2. The Fanconi anemia pathway sensitizes to DNA alkylating agents by inducing JNK-p53-dependent mitochondrial apoptosis in breast cancer cells.
Zhao L; Li Y; He M; Song Z; Lin S; Yu Z; Bai X; Wang E; Wei M
Int J Oncol; 2014 Jul; 45(1):129-38. PubMed ID: 24789349
[TBL] [Abstract][Full Text] [Related]
3. RNAi-mediated knockdown of FANCF suppresses cell proliferation, migration, invasion, and drug resistance potential of breast cancer cells.
Zhao L; Li N; Yu JK; Tang HT; Li YL; He M; Yu ZJ; Bai XF; Zheng ZH; Wang EH; Wei MJ
Braz J Med Biol Res; 2014 Jan; 47(1):24-34. PubMed ID: 24345874
[TBL] [Abstract][Full Text] [Related]
4. Gene silencing of FANCF potentiates the sensitivity to mitoxantrone through activation of JNK and p38 signal pathways in breast cancer cells.
Li Y; Zhao L; Sun H; Yu J; Li N; Liang J; Wang Y; He M; Bai X; Yu Z; Zheng Z; Mi X; Wang E; Wei M
PLoS One; 2012; 7(8):e44254. PubMed ID: 22952942
[TBL] [Abstract][Full Text] [Related]
5. Function of the Fanconi anemia pathway in Fanconi anemia complementation group F and D1 cells.
Siddique MA; Nakanishi K; Taniguchi T; Grompe M; D'Andrea AD
Exp Hematol; 2001 Dec; 29(12):1448-55. PubMed ID: 11750104
[TBL] [Abstract][Full Text] [Related]
6. RNA interference-mediated FANCF silencing sensitizes OVCAR3 ovarian cancer cells to adriamycin through increased adriamycin-induced apoptosis dependent on JNK activation.
He M; Sun HG; Hao JY; Li YL; Yu JK; Yan YY; Zhao L; Li N; Wang Y; Bai XF; Yu ZJ; Zheng ZH; Mi XY; Wang EH; Wei MJ
Oncol Rep; 2013 May; 29(5):1721-9. PubMed ID: 23440494
[TBL] [Abstract][Full Text] [Related]
7. RNA interferences targeting the Fanconi anemia/BRCA pathway upstream genes reverse cisplatin resistance in drug-resistant lung cancer cells.
Dai CH; Li J; Chen P; Jiang HG; Wu M; Chen YC
J Biomed Sci; 2015 Sep; 22(1):77. PubMed ID: 26385482
[TBL] [Abstract][Full Text] [Related]
8. Promoter hypermethylation of FANCF plays an important role in the occurrence of ovarian cancer through disrupting Fanconi anemia-BRCA pathway.
Wang Z; Li M; Lu S; Zhang Y; Wang H
Cancer Biol Ther; 2006 Mar; 5(3):256-60. PubMed ID: 16418574
[TBL] [Abstract][Full Text] [Related]
9. Heterogeneous activation of the Fanconi anemia pathway by patient-derived FANCA mutants.
Adachi D; Oda T; Yagasaki H; Nakasato K; Taniguchi T; D'Andrea AD; Asano S; Yamashita T
Hum Mol Genet; 2002 Dec; 11(25):3125-34. PubMed ID: 12444097
[TBL] [Abstract][Full Text] [Related]
10. Disruption of the FA/BRCA pathway in bladder cancer.
Neveling K; Kalb R; Florl AR; Herterich S; Friedl R; Hoehn H; Hader C; Hartmann FH; Nanda I; Steinlein C; Schmid M; Tonnies H; Hurst CD; Knowles MA; Hanenberg H; Schulz WA; Schindler D
Cytogenet Genome Res; 2007; 118(2-4):166-76. PubMed ID: 18000367
[TBL] [Abstract][Full Text] [Related]
11. The Fanconi anemia protein FANCF forms a nuclear complex with FANCA, FANCC and FANCG.
de Winter JP; van der Weel L; de Groot J; Stone S; Waisfisz Q; Arwert F; Scheper RJ; Kruyt FA; Hoatlin ME; Joenje H
Hum Mol Genet; 2000 Nov; 9(18):2665-74. PubMed ID: 11063725
[TBL] [Abstract][Full Text] [Related]
12. Involvement of Fanconi anemia genes FANCD2 and FANCF in the molecular basis of drug resistance in leukemia.
Yao C; Du W; Chen H; Xiao S; Huang L; Chen FP
Mol Med Rep; 2015 Jun; 11(6):4605-10. PubMed ID: 25647473
[TBL] [Abstract][Full Text] [Related]
13. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors.
Taniguchi T; Tischkowitz M; Ameziane N; Hodgson SV; Mathew CG; Joenje H; Mok SC; D'Andrea AD
Nat Med; 2003 May; 9(5):568-74. PubMed ID: 12692539
[TBL] [Abstract][Full Text] [Related]
14. Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer.
Narayan G; Arias-Pulido H; Nandula SV; Basso K; Sugirtharaj DD; Vargas H; Mansukhani M; Villella J; Meyer L; Schneider A; Gissmann L; Dürst M; Pothuri B; Murty VV
Cancer Res; 2004 May; 64(9):2994-7. PubMed ID: 15126331
[TBL] [Abstract][Full Text] [Related]
15. Bi-allelic silencing of the Fanconi anaemia gene FANCF in acute myeloid leukaemia.
Tischkowitz M; Ameziane N; Waisfisz Q; De Winter JP; Harris R; Taniguchi T; D'Andrea A; Hodgson SV; Mathew CG; Joenje H
Br J Haematol; 2003 Nov; 123(3):469-71. PubMed ID: 14617007
[TBL] [Abstract][Full Text] [Related]
16. Variation in cisplatinum sensitivity is not associated with Fanconi Anemia/BRCA pathway inactivation in head and neck squamous cell carcinoma cell lines.
Snyder ER; Ricker JL; Chen Z; Waes CV
Cancer Lett; 2007 Jan; 245(1-2):75-80. PubMed ID: 16466850
[TBL] [Abstract][Full Text] [Related]
17. The Fanconi anemia/BRCA pathway is involved in DNA interstrand cross-link repair of adriamycin-resistant leukemia cells.
Yao C; Du W; Chen H; Xiao S; Huang L; Chen F
Leuk Lymphoma; 2015 Mar; 56(3):755-62. PubMed ID: 24996439
[TBL] [Abstract][Full Text] [Related]
18. Fanconi anemia protein complex: mapping protein interactions in the yeast 2- and 3-hybrid systems.
Gordon SM; Buchwald M
Blood; 2003 Jul; 102(1):136-41. PubMed ID: 12649160
[TBL] [Abstract][Full Text] [Related]
19. Low incidence of methylation of the promoter region of the FANCF gene in Japanese primary breast cancer.
Tokunaga E; Okada S; Kitao H; Shiotani S; Saeki H; Endo K; Morita M; Kakeji Y; Maehara Y
Breast Cancer; 2011 Apr; 18(2):120-3. PubMed ID: 19813073
[TBL] [Abstract][Full Text] [Related]
20. Ouabain, a cardiac glycoside, inhibits the Fanconi anemia/BRCA pathway activated by DNA interstrand cross-linking agents.
Jun DW; Hwang M; Kim HJ; Hwang SK; Kim S; Lee CH
PLoS One; 2013; 8(10):e75905. PubMed ID: 24124520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]